Open AccessNab-paclitaxel monotherapy in patients with metastatic breast cancer with visceral crisis: evaluation of efficacy and tolerability in clinical practice
Author(s) -
Л. Ю. Владимирова,
К. А. Новосёлова,
Irina L. Popova,
Natalya A Abramova,
Н. М. Тихановская,
А. А. Льянова,
Л. А. Рядинская,
М. О. Ежова,
М. А. Теплякова,
Anna V. Tishina,
Е. В. Приходько
Publication year - 2019
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2019-10-81-86
Subject(s) - medicine , tolerability , nausea , metastatic breast cancer , breast cancer , paclitaxel , oncology , toxicity , chemotherapy , cancer , adverse effect
The authors analysed the efficacy and safety of Nab-paclitaxel (Nab-R) monotherapy in patients with metastatic breast cancer with visceral crisis (VC) in the second- and further-line chemotherapy. The objective response rate (ORR) was 35.3% (6 of 17 persons). The most frequent side effects were general weakness, nausea, symptoms of peripheral neuropathy. The degree of toxicity did not exceed 1–2 in 60% of cases. The median time to progression was 7.8 months. (95% CI 6–10.6). The median overall survival for patients with VC was 14.9 months. (95% CI 12.0–16.9). Efficacy and controlled toxicity of Nab-P allows its use in pre-treated patients, including ones with VC.